Zacks Premium - Zacks Premium提供多种方式帮助投资者更加聪明和自信[1] - Zacks Style Scores是根据价值、增长和动量质量对股票进行评级的指标[4] - 通过结合Zacks Rank和Style Scores，投资者可以选择具有最高成功概率的股票[14] DexCom - DexCom是一家医疗器械公司，专注于连续葡萄糖监测系统的设计和开发[17]

In the latest market close, DexCom (DXCM) reached $127.12, with a -1.68% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.29%. Elsewhere, the Dow lost 0.25%, while the tech-heavy Nasdaq added 0.43%.Heading into today, shares of the medical device company had gained 5.83% over the past month, outpacing the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08% in that time.Investors will be eagerly watching for the performance of DexCom in its up ...

While many economists predicted a recession in 2023, and macro volatility remains a factor that consumers and investors are still contending with, the grave headwinds many awaited with trepidation have yet to appear. Now, volatility might still lie ahead for many industries and companies, but the wider economy appears to be improving slowly but surely.If you're looking for stable businesses to put cash to work, healthcare has proved to be considerably less vulnerable to economic fluctuations than other indu ...

Dexcom新工厂 - Dexcom, Inc. (DXCM)最近在爱尔兰加尔韦郡揭开了其全新的先进制造工厂[1] - 这家新工厂将有能力每年生产数百万个Dexcom rtCGM传感器，有望为欧洲、中东和非洲地区的糖尿病患者带来改善[2] - Dexcom的首个欧洲制造工厂将保证产品在欧洲、中东和非洲地区的流动，有望通过缩短运输交货时间来降低成本并改善可持续性[6] - 这家新工厂预计每年将有能力生产数百万个Dexcom rtCGM传感器，并有望在该地区创造就业机会[7] Dexcom在欧洲市场 - DexCom目前正在多个国际市场扩张，欧洲市场占据了重要地位。这家工厂可能有助于DexCom在欧洲支持其rtCGM传感器的供应[9] - 据Mordor Intelligence的报告，欧洲连续血糖监测（CGM）市场预计到2024年将价值20.4亿美元，并将以11.33%的增长率增至2029年的34.7亿美元[10] Dexcom的最新技术 - DexCom最近宣布，南非和许多欧洲国家现在可以将其最新的G7 CGM系统连接到Tandem Diabetes Care的t: slim X2胰岛素泵上，后者具有Control-IQ技术[11]

DexCom, Inc. (DXCM) is well poised for growth in the coming quarters, backed by its strong product portfolio. A robust third-quarter 2023 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist.This currently Zacks Rank #3 (Hold) company’s shares have risen 19.9% in the past year against the industry’s 0.2% decline. The S&P 500 Index has increased 22.2% in the same time frame.DXCM, a renowned medical device comp ...

股价表现 - DexCom (DXCM) 最新收盘价为 $125.45，较前一天上涨了 +0.8% [1] - DexCom 过去一个月的股价上涨了 0.95%，落后于医疗行业的 3.8% 和标普500指数的 1.2% [2] 财务预期 - DexCom 将于 2024年2月8日发布财报，预计每股收益为 $0.43，同比增长 26.47%，预计营收为 $1.03 亿美元，同比增长 26.35% [3] - DexCom 目前的 Forward P/E 比率为 72.89，高于行业平均值 25.93 [7] 分析师观点 - 分析师对 DexCom 的最新预期变化表明他们对公司业务运营和盈利能力持乐观态度 [4] - DexCom 目前的 Zacks Rank 为 3 (Hold)，过去一个月 Zacks Consensus EPS 预期上涨了 0.49% [6] 行业比较 - DXCM 目前的 PEG 比率为 2.17，医疗仪器行业的平均 PEG 比率为 2.23 [8] - 医疗仪器行业的 Zacks Industry Rank 为 152，位于所有 250+ 行业的后 40% [9] 投资建议 - 研究表明分析师对股价表现的预期变化与即将到来的股价表现直接相关，投资者可以利用 Zacks Rank 模型来获取投资机会 [5] - 利用 Zacks.com 来及时了解这些股票变动指标等信息 [11]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? DexCom (DXCM) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.This medical device company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 50.80%.For the last reported quarter, DexCom came out ...

Important voices in the investment world predict that 2024 could be a very strong year for mid-cap stocks. Janus Henderson portfolio manager Brian Demain believes the outlook for mid caps looks favorable as rate hikes slow and cuts draw nearer. Demain also anticipates that they could perform very well due to their relative underperformance to large cap stocks in 2023.Other prominent investors including Fundstrat head Tom Lee also expect large cap stocks to become less important. So, mid-cap equities will be ...

DexCom, Inc. (DXCM) recently announced preliminary revenue results for fourth-quarter 2023. The preliminary results drove up the company’s shares by 4.6% in the trading session on Jan 8.The company is scheduled to release fourth-quarter results on Feb 8.Per the preliminary report, fourth-quarter 2023 net sales are estimated to be at least $1.03 billion, up 26% year over year. The Zacks Consensus Estimate of $1.0 billion lies below the preliminary figure.The company recorded sales of approximately $765 milli ...

Zacks Style Scores - Zacks Premium提供了多种方式帮助投资者更加聪明和自信地投资[1] - Zacks Style Scores是一组辅助指标，帮助投资者挑选具有在未来30天内击败市场机会最大的股票[4] - Style Scores分为价值评分、成长评分、动量评分和VGM评分，分别帮助投资者找到具有吸引力的股票、长期可持续增长的股票和利用股价或盈利前景趋势的股票[6][7][8][9]